Anthem Biosciences Intrinsic Value
ANTHEM Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹271.92 | ₹217.54 - ₹326.30 | -56.8% | EPS: ₹12.36, Sector P/E: 22x |
| Book Value Method | asset | ₹430.36 | ₹387.32 - ₹473.40 | -31.7% | Book Value/Share: ₹215.18, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹427.14 | ₹384.43 - ₹469.85 | -32.2% | Revenue/Share: ₹213.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹948.19 | ₹853.37 - ₹1043.01 | +50.6% | EBITDA: ₹1064.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹432.02 | ₹345.62 - ₹518.42 | -31.4% | CF Growth: 10.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹188.91 | ₹170.02 - ₹207.80 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹190.96 | ₹171.86 - ₹210.06 | -69.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹988.57 | ₹889.71 - ₹1087.43 | +57.0% | ROE: 28.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹244.62 | ₹220.16 - ₹269.08 | -61.2% | EPS: ₹12.36, BVPS: ₹215.18 |
Want to compare with current market value? Check ANTHEM share price latest .
Valuation Comparison Chart
ANTHEM Intrinsic Value Analysis
What is the intrinsic value of ANTHEM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Anthem Biosciences (ANTHEM) is ₹427.14 (median value). With the current market price of ₹629.70, this represents a -32.2% variance from our estimated fair value.
The valuation range spans from ₹188.91 to ₹988.57, indicating ₹188.91 - ₹988.57.
Is ANTHEM undervalued or overvalued?
Based on our multi-method analysis, Anthem Biosciences (ANTHEM) appears to be trading above calculated value by approximately 32.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 24.12 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.17 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 28.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 40.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Anthem Biosciences
Additional stock information and data for ANTHEM
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹418 Cr | ₹342 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹140 Cr | ₹29 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹306 Cr | ₹118 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹333 Cr | ₹231 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹278 Cr | ₹180 Cr | Positive Free Cash Flow | 8/10 |